Skip to main content

Table 1 Off-label use of tocilizumab (TCZ) in pediatric patients with Takayasu arteritis

From: Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Authors, year (ref.) Sex Age at onset, years Age at TCZ, years Manifestations Previous therapy Dose of TCZ Duration of TCZ, months Adverse effect of TCZ  
Bravo Mancheno et al., 2012 [38] F 3 5 Wall thickening, occlusion GC, MTX, ETN, IFX, CYC, MMF 8 mg/kg /2–3 weeks > 24 No
Batu et al., 2017 [39] F 4 9 Stenosis GC, CYC, MTX, AZA 8 mg/kg /4 weeks 7–13 No  
F 13 15 Aneurysms
F 16 16 Graft, stenosis and aneurysms GC, CYC, MTX
GC, CYC, ETN
F 16 16 Wall thickening GC
Decker et al., 2018 [40] F 13 15 Panaortitis GC, MTX, IFX 8 mg/kg /4 weeks 18 No  
Canas et al., 2014 [41] F 12   Wall thickening GC 8 mg/kg /4 weeks 18 No  
F 14 Wall thickening GC, MTX 12
Goel et al., 2013 [42] F 13 13 In-stent restenosis GC, MMF 8 mg/kg /4 weeks 6 No serious AE  
In-stent restenosis GC, MMF
F 14 15
  1. GC glucocorticoids, MTX methotrexate, ETN etanercept, IFX infliximab, CYC cyclophosphamide, MMF mycophenolate mofetil, AZA azathioprine